Neuropace Inc

NASDAQ NPCE
$9.73 0.12 1.25%
Today share price
USA
Sector: Healthcare Industry: Medical Devices
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 21.25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
386.90M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
421.59M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
31.48M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-13.05 %

Upcoming events Neuropace Inc

All events
No upcoming events scheduled

Stock chart Neuropace Inc

Stock analysis Neuropace Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-15.60 -2.59
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
40.67 1.36
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-37.26 -2.52
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-3.07 0.34
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-102.21 -40.86

Price change Neuropace Inc per year

5.90$ 18.13$
Min Max

Summary analysis Neuropace Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Neuropace Inc

Revenue and net income Neuropace Inc

All parameters

About company Neuropace Inc

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides Physician Tablet, Patient Data Management System, and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Address:
455 North Bernardo Avenue, Mountain View, CA, United States, 94043
Company name: Neuropace Inc
Issuer ticker: NPCE
ISIN: US6412881053
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2021-04-22
Sector: Healthcare
Industry: Medical Devices
Site: https://www.neuropace.com